{"doi":"10.1002/art.42916","title":"Antibodies to Malondialdehyde‐Acetaldehyde Adduct Are Associated With Prevalent and Incident Rheumatoid Arthritis–Associated Interstitial Lung Disease in <scp>US</scp> Veterans","abstract":"OBJECTIVE: The objective of this study is to determine the associations of protein-specific anti-malondialdehyde-acetaldehyde (MAA) antibodies with prevalent and incident rheumatoid arthritis-interstitial lung disease (RA-ILD). METHODS: Within a multicenter, prospective cohort of US veterans with RA, RA-ILD was validated by medical record review of clinical diagnoses, chest imaging, and pathology. Serum antibodies to MAA-albumin, MAA-collagen, MAA-fibrinogen, and MAA-vimentin (IgA, IgM, and IgG) were measured by a standardized enzyme-linked immunosorbent assay. Associations of anti-MAA antibodies with prevalent and incident RA-ILD were assessed using multivariable regression models adjusting for established RA-ILD risk factors. RESULTS: Among 2,739 participants with RA (88% male, mean age of 64 years), there were 114 with prevalent and 136 with incident RA-ILD (average time to diagnosis: 6.6 years). Higher IgM anti-MAA-collagen (per 1 SD: adjusted odds ratio [aOR] 1.28, 95% confidence interval [CI] 1.02-1.61), IgA anti-MAA-fibrinogen (aOR 1.48, 95% CI 1.14-1.92), and IgA (aOR 1.78, 95% CI 1.34-2.37) and IgG (aOR 1.48, 95% CI 1.14-1.92) anti-MAA-vimentin antibodies were associated with prevalent RA-ILD. In incident analyses, higher IgA (per one SD: adjusted hazards ratio [aHR] 1.40, 95% CI 1.11-1.76) and IgM (aHR 1.29, 95% CI 1.04-1.60) anti-MAA-albumin antibody concentrations were associated with increased ILD risk. Participants with IgA (aHR 2.13, 95% CI 1.16-3.90) or IgM (aHR 1.98, 95% CI 1.08-3.64) anti-MAA-albumin antibody concentrations in the highest quartile had an approximately two-fold increased risk of incident RA-ILD. Across all isotypes, anti-MAA-fibrinogen, anti-MAA-collagen, and anti-MAA-vimentin antibodies were not significantly associated with incident RA-ILD. CONCLUSION: Protein-specific anti-MAA antibodies to collagen, fibrinogen, and vimentin were associated with prevalent RA-ILD. IgA and IgM anti-MAA-albumin antibodies were associated with a higher risk of incident RA-ILD. These findings suggest that MAA modifications and resultant immune responses may contribute to RA-ILD pathogenesis.","journal":"Arthritis & Rheumatology","year":2024,"id":453635,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.886,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":342502,"name":"Geoffrey M. Thiele","orcid":"0000-0001-5688-8596","position":1,"is_corresponding":false},{"id":366000,"name":"Michael J. Duryee","orcid":"0000-0001-9104-2238","position":2,"is_corresponding":false},{"id":367736,"name":"Carlos D. Hunter","orcid":null,"position":3,"is_corresponding":false},{"id":315984,"name":"Yangyuna Yang","orcid":null,"position":4,"is_corresponding":false},{"id":315983,"name":"Punyasha Roul","orcid":null,"position":5,"is_corresponding":false},{"id":685291,"name":"Dana P. Ascherman","orcid":"0000-0002-1387-0860","position":6,"is_corresponding":false},{"id":476885,"name":"Scott M. Matson","orcid":"0000-0002-3748-9597","position":7,"is_corresponding":false},{"id":862588,"name":"Gary Kunkel","orcid":null,"position":8,"is_corresponding":false},{"id":755682,"name":"Grant W. Cannon","orcid":"0000-0001-6640-9173","position":9,"is_corresponding":false},{"id":497055,"name":"Katherine D. Wysham","orcid":"0000-0001-8707-7649","position":10,"is_corresponding":false},{"id":755681,"name":"Gail S. Kerr","orcid":"0000-0002-4930-3235","position":11,"is_corresponding":false},{"id":61593,"name":"Paul A. Monach","orcid":"0000-0003-4937-0515","position":12,"is_corresponding":false},{"id":305808,"name":"Joshua F. Baker","orcid":"0000-0003-0799-7563","position":13,"is_corresponding":false},{"id":457086,"name":"Jill A. Poole","orcid":"0000-0002-6236-2563","position":14,"is_corresponding":false},{"id":314417,"name":"Ted R. Mikuls","orcid":"0000-0002-0897-2272","position":15,"is_corresponding":false},{"id":314415,"name":"Bryant R. England","orcid":"0000-0002-9649-3588","position":16,"is_corresponding":false},{"id":903684,"name":"Nozima Aripova","orcid":"0000-0002-0920-8807","position":0,"is_corresponding":true}],"reference_count":51,"raw_metadata":null,"created_at":"2026-07-19T02:03:03.428151Z","pmid":"38766737","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}